MarketCap
Facebook
X
TelegramQuarterly report 2022-Q1
added 12-23-2023
Genocea Biosciences Retained Earnings 2011-2026 | GNCA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Genocea Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -408 M | -375 M | -331 M | -292 M | -264 M | -207 M | -158 M | -115 M | -80.1 M | -58.4 M | -43.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.6 M | -408 M | -212 M |
Quarterly Retained Earnings Genocea Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -424 M | -408 M | -395 M | -391 M | -387 M | -375 M | -360 M | -375 M | -344 M | -331 M | -331 M | -331 M | -331 M | -292 M | -292 M | -292 M | -292 M | -264 M | -264 M | -264 M | -264 M | -207 M | -207 M | -207 M | -207 M | -158 M | -158 M | -158 M | -158 M | -115 M | -115 M | -115 M | -115 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -80.1 M | -424 M | -250 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.95 | -1.27 % | $ 498 M |  Britain |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.1 | 1.31 % | $ 7.46 B |  Australia |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.09 | -2.25 % | $ 5.94 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.14 | 0.49 % | $ 1.68 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 212.41 | 1.48 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 11.67 | 0.56 % | $ 768 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.2 | 6.23 % | $ 435 M |  Israel |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 94.97 | -0.33 % | $ 27.2 B | Germany |
 |
Certara
CERT
|
-128 M | $ 8.78 | -0.9 % | $ 1.41 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 26.71 | -1.07 % | $ 1.29 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.6 | 0.52 % | $ 141 M | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 4.74 | -0.84 % | $ 116 M | France |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 570.58 | -0.27 % | $ 43.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 92.13 | -0.41 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
-182 M | - | -0.88 % | $ 598 M | USA |
 |
CorMedix
CRMD
|
-322 M | $ 11.85 | -5.05 % | $ 603 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 27.35 | 3.48 % | $ 1.76 M | USA |